Amygdalin (Laetrile) and HIV: Absence of Antiretroviral Activity and Documented Cyanide Toxicity

1. Introduction: A Persistent Myth in the Shadow of the AIDS Crisis

Among the many unproven substances promoted during the first two decades of the HIV/AIDS epidemic, amygdalin — most often marketed under the name laetrile or «vitamin B17» — occupies a distinctive and troubling place. It was not merely ineffective; it is a cyanogenic compound whose oral ingestion can release hydrogen cyanide, a potent mitochondrial poison. The history of its promotion for HIV is inseparable from a larger episode in which desperation, distrust of medicine, and the appeal of «natural» remedies converged to offer false hope to people facing a then-lethal diagnosis.

This article examines amygdalin and laetrile specifically in the context of HIV. It summarizes the established chemistry and toxicology, evaluates the HIV-specific claims that were made, explains why no coherent antiretroviral mechanism exists, contrasts the substance with the cancer evidence base, and reviews the documented harms, regulatory status, and reasons the claims have persisted. A companion article addresses amygdalin in cancer. No claim of efficacy against HIV is made here; on the contrary, the available evidence supports the conclusion that amygdalin has no established antiretroviral activity and carries a real risk of cyanide poisoning.

2. The Chemistry of Amygdalin: A Cyanogenic Glycoside

2.1. Molecular Identity and Natural Sources

Amygdalin (C₂₀H₂₇NO₁₁) is a cyanogenic glycoside. Its core is a mandelonitrile moiety — a molecule that stores cyanide in a chemically bound, non-toxic form — glycosylated with two glucose units. The compound is widespread in the seeds and kernels of the Rosaceae family, including bitter almond kernels, apricot and peach pits, apple seeds, cherry and plum pits, and the kernels of several other stone fruits. The characteristic bitter taste of these tissues is itself a chemosensory warning of their cyanogenic content.

2.2. Enzymatic Hydrolysis and the Release of Cyanide

Amygdalin is not intrinsically a poison; it becomes one when its glycosidic bonds are cleaved. Plant tissues contain compartmentalized hydrolytic enzymes — an amygdalin β-glucosidase (amygdalin hydrolase) and a prunasin hydrolase — that are released when cells are disrupted by chewing, crushing, or grinding. The stepwise hydrolysis proceeds from amygdalin to prunasin, then to mandelonitrile, and finally to benzaldehyde plus free hydrogen cyanide (HCN). Critically for human risk, the β-glucosidases of the gut microbiome can perform the same deglycosylation after a person swallows amygdalin, meaning that hydrolysis can occur in vivo even if the ingested material is not a crushed plant cell.

This enzymatic release explains the central toxicological feature of the substance: the hazard is greatest by the oral route, because the large intestine provides a rich enzymatic environment that converts a nominally inert glycoside into systemically absorbed cyanide. Intravenous preparations avoid first-pass gut metabolism but do not eliminate the risk, since the parent compound can still be metabolized.

2.3. «Laetrile» and «Vitamin B17»: Nomenclature and Marketing

The term laetrile is commonly applied to a semi-synthetic derivative of amygdalin — most often the glucuronide conjugate (mandelonitrile glucuronide), which is structurally related to but not identical with the natural diglucoside. In popular commerce the two names have been used almost interchangeably, and both have been sold as «vitamin B17.» That label is a marketing term, not a scientific designation: amygdalin is not a vitamin, is not required by human metabolism, and its deficiency produces no recognised syndrome. The «B17» framing was a deliberate rhetorical device that positioned a toxic glycoside alongside genuine micronutrients.

3. Cyanide as a Mitochondrial Toxin: Mechanism and Clinical Toxicology

Hydrogen cyanide is a rapidly acting, systemically distributed poison. Its principal molecular target is cytochrome c oxidase (Complex IV), the terminal enzyme of the mitochondrial electron transport chain. Cyanide binds to the ferric iron at the enzyme’s heme a₃ site, blocking the transfer of electrons to molecular oxygen. Oxidative phosphorylation halts, ATP production collapses, and cells shift to anaerobic metabolism with lactic acidosis. Because oxygen cannot be used at the tissue level, the clinical picture is that of «histotoxic hypoxia»: cells cannot extract oxygen even when the blood is fully saturated.

Tissues with the highest metabolic demand are affected first — the central nervous system and the heart. Early features include headache, confusion, dizziness, nausea, and rapid breathing; severe exposure progresses to seizures, coma, cardiovascular collapse, and death within minutes to hours. Antidotes (hydroxocobalamin, and historically sodium nitrite plus sodium thiosulfate) act to bind or accelerate the elimination of cyanide, and outcomes depend heavily on the dose and the speed of treatment. Individuals with underlying metabolic or neurological conditions may tolerate cyanide poorly, and repeated low-level exposures can produce chronic symptoms such as neuropathy. **[Marked for verification.]**

4. The HIV-Specific Claims: What Was Promised

4.1. The «Metabolic Therapy» Era

During the 1980s and 1990s, when effective antiretroviral therapy did not yet exist or was still rudimentary, amygdalin and related «metabolic» regimens were promoted in some alternative-medicine circles as immune boosters and as treatments for AIDS. These claims generally framed laetrile as a broad «detoxifying» or cell-normalising agent rather than as a targeted antiviral. Testimonials and clinic brochures substituted for controlled data, and the substances were frequently delivered alongside other unproven products. The precise network of promoters and clinics, and the extent of their claims, is historically heterogeneous and difficult to document exhaustively; specific assertions about particular clinics or practitioners should be treated with caution. **[Marked for verification.]**

4.2. The Discredited «Selectivity» Hypothesis

The intellectual foundation of the laetrile movement was the claim of selective toxicity: that cyanide would be liberated preferentially in «diseased» cells — cancer cells, or in the AIDS setting, virally infected or immunologically abnormal cells — while normal cells would be protected by their detoxifying enzymes. Proponents invoked differences in enzymes such as rhodanese (thiosulfate sulfurtransferase) and β-glucuronidase to argue that cyanide released from laetrile would accumulate where it was wanted. This hypothesis was never substantiated and is now regarded as discredited. Independent analysis found no reliable biochemical basis for lesion-selective cyanide release, and the premise that diseased cells would be spared-free was contradicted by direct toxicological observation. The same reasoning was simply transferred, without new evidence, from the cancer context to HIV.

5. Why Amygdalin Cannot Act Against HIV: Absent Mechanisms

5.1. No Activity Against Any Established Antiretroviral Target

Every approved antiretroviral drug acts at one of a small number of precisely characterised steps in the HIV life cycle: viral entry and fusion, reverse transcription of the RNA genome, integration of proviral DNA, or proteolytic maturation of viral proteins. Amygdalin has no established activity against any of these targets. It does not inhibit reverse transcriptase, protease, or integrase, and it does not block viral entry or fusion. There is no coherent mechanism by which a cyanogenic glycoside, or the cyanide it releases, would specifically interfere with retroviral replication. Cyanide is a general metabolic poison, not an antiviral: its cellular actions are indiscriminate and would damage host cells well before any theoretical effect on the virus.

5.2. No Plausible HIV-Selectivity

Even if one entertained the notion that cyanide could harm infected cells, there is no credible mechanism by which it would spare uninfected CD4+ T cells, macrophages, and other cell types essential to immune function. HIV infection does not create the kind of selective enzymatic vulnerability the laetrile hypothesis required. On the contrary, widespread cyanide exposure threatens exactly the tissues whose preservation is needed to control the infection. The «immune-boosting» claim is therefore internally contradictory: the proposed agent is a mitochondrial toxin with the capacity to impair immune cell function.

5.3. Absence of Controlled Trial Evidence in HIV

It is important to state the evidential position plainly. For HIV specifically, there is no controlled clinical trial evidence of any kind — no randomised trial, no controlled cohort, no rigorous virological or immunological endpoint — showing benefit from amygdalin or laetrile. The claims rest entirely on anecdote, on extrapolation from the cancer literature, and on the discredited selectivity hypothesis. In the hierarchy of medical evidence, this places amygdalin at the level of unsubstantiated assertion, not of preliminary but promising research.

6. The Cancer Evidence as a Proxy: The Moertel Trial and Its Lessons

Because no HIV trial exists, the most instructive evidence comes from the cancer setting, where the substance was formally tested. The U.S. National Cancer Institute sponsored a controlled clinical trial of amygdalin (laetrile) led by Charles G. Moertel and colleagues, published in the New England Journal of Medicine in 1982. In that study, patients with advanced cancer received amygdalin and were followed for objective tumour response. The trial found no objective responses — no complete or partial tumour regression attributable to the treatment — and documented evidence of cyanide toxicity in some participants, including elevated blood cyanide levels and clinical symptoms. **[Citation details to be verified.]**

The Moertel trial is important for the HIV discussion not because cancer and HIV are biologically similar, but because it tested the central claims of the laetrile movement directly and refuted them. It demonstrated that the substance lacked the selective antitumour activity proponents had asserted, and that the toxicological mechanism was real and clinically relevant. If amygdalin failed to show efficacy in the disease for which it was most aggressively promoted, there is no scientific basis to expect efficacy in a different disease for which no controlled data exist at all.

7. Documented Harm: Acute and Fatal Cyanide Poisoning

7.1. Poisoning from Amygdalin and Apricot Kernels

Cases of acute and fatal cyanide poisoning following the ingestion of amygdalin, laetrile preparations, and raw apricot kernels have been documented in the medical and poison-control literature. These include severe and fatal outcomes, and importantly they include children, who are especially vulnerable because of their lower body mass and higher metabolic rate. The presentation is consistent with cyanide toxicity: rapid onset of neurological and cardiovascular deterioration, sometimes progressing to death. Poison centres and toxicology services have repeatedly cautioned the public against consuming stone-fruit kernels or laetrile products. **[Marked for verification.]** for individual case details.

7.2. Why the Oral Route Is the Most Dangerous

The oral route carries the greatest risk because gut bacterial β-glucosidases release cyanide from amygdalin within the intestinal tract, where it is readily absorbed. Individual susceptibility varies with the composition of the gut microbiome, the amount and formulation ingested, whether the material was crushed (releasing plant enzymes), and fasting status. This variability makes the dose-effect relationship unpredictable and means that even quantities that have previously been tolerated can, on another occasion, produce serious toxicity. There is no reliable «safe dose» for a substance whose toxicity depends on the consumer’s own gut flora.

7.3. Interactions and Co-Ingestion

Because amygdalin was typically used as part of multi-component «metabolic» or alternative regimens, co-ingestion with other substances was common. This creates the potential for unpredictable interactions — both with the kinetics of cyanide release and with the detoxification pathways on which the body depends. There is no systematic safety data on such combinations. A further practical hazard is that people using these products may delay or abandon effective antiretroviral therapy, exposing themselves to uncontrolled viral replication and disease progression.

8. Regulatory Status and Legal Standing

Amygdalin and laetrile are not approved as drugs by the U.S. Food and Drug Administration (FDA). The FDA has determined that they are not recognised as safe and effective for any indication, and it has acted to block their interstate distribution and importation for drug use. In the late 1970s the agency’s position was upheld in litigation, and the U.S. Supreme Court affirmed the FDA’s authority to require proof of efficacy before a drug may be marketed, rejecting the argument that terminally ill patients had a constitutional right of access to unproven treatments. **[Marked for verification.]** Equivalent regulatory bodies in other jurisdictions have taken comparable positions, and in many countries the importation or sale of laetrile for medicinal use is restricted or illegal.

The label «vitamin B17» has no regulatory or scientific standing. It does not denote an approved nutrient, and its use is a marketing device intended to lend a supplement-like respectability to a compound that is otherwise a regulated (and toxic) drug candidate. Consumers should understand that «vitamin B17» products are neither vitamins nor validated medicines.

9. Why the Claims Persist: Psychology, Distrust, and the Cost of Delay

The persistence of amygdalin claims is a case study in the psychology of unproven remedies. Three forces are consistently involved. First is the appeal of the «natural»: a substance derived from fruit kernels can be framed as gentle, traditional, and outside a pharmaceutical industry that many people distrust. Second is distrust itself — of regulators, of medicine, and of the institutions that had, in the early epidemic years, sometimes failed communities affected by HIV. Third, and most powerful, is desperation: before effective therapy existed, people facing a fatal diagnosis had every reason to grasp at anything offering hope, and later, when therapy did arrive, some continued to seek alternatives.

These forces are understandable but the consequences are not benign. The principal danger of unproven «immune boosters» is not only direct toxicity but indirect harm: delaying or replacing effective antiretroviral therapy. Modern combination therapy suppresses HIV to undetectable levels, restores immune function, prevents transmission, and allows near-normal life expectancy. Any decision to substitute amygdalin for such treatment exposes a person to AIDS-defining illness, opportunistic infection, and death from a condition that is, today, manageable. The ethical imperative in evaluating amygdalin in HIV is therefore not only to note the absence of efficacy but to recognise the harm caused by false reassurance.

10. Conclusion

Amygdalin and laetrile have no established role in the treatment of HIV. The substance is a cyanogenic glycoside that releases hydrogen cyanide — a mitochondrial toxin targeting cytochrome c oxidase — particularly when taken orally and acted upon by gut bacterial enzymes. There is no credible antiretroviral mechanism: no inhibition of reverse transcriptase, protease, integrase, or viral entry, and no plausible means of selectively harming infected cells while sparing the immune system. No controlled trial has shown any benefit in HIV, and the disease for which it was actually tested, cancer, produced a definitive negative result in an NCI-sponsored randomised trial that also documented cyanide toxicity. Documented cases of acute and fatal poisoning, including in children, underscore the real hazard.

Regulators have not approved amygdalin or laetrile as drugs, and «vitamin B17» is a marketing term with no scientific basis. The claims persist for reasons rooted in hope, distrust, and the history of the epidemic — not in data. People living with HIV have access to highly effective, well-monitored antiretroviral therapy; substituting an unproven and potentially lethal cyanogenic substance for it is a choice that can cost lives. This article concerns HIV specifically; the cancer evidence and its accompanying controversies are addressed in a companion article. Nothing here should be read as endorsing any use of amygdalin or laetrile for any condition.

Sources and Key Research Centers

1. U.S. Food and Drug Administration (FDA)
   • The U.S. regulator that has determined amygdalin and laetrile are not recognised as safe and effective for any indication and has restricted their distribution and importation for drug use. A primary source for the regulatory position discussed in Section 8.
2. National Cancer Institute (NCI)
   • The NCI sponsored the controlled clinical trial of amygdalin (laetrile) in cancer reported by Moertel and colleagues, and maintains patient-facing and professional information on unproven treatments. A key source for the cancer evidence used as a proxy in Section 6.
   • Key Publication: Moertel, C.G., et al. «A clinical trial of amygdalin (Laetrile) in the treatment of human cancer.» New England Journal of Medicine, 1982. **[Citation details to be verified.]**
3. U.S. National Library of Medicine — PubMed
   • The bibliographic database through which the primary literature on amygdalin toxicology, cyanide poisoning case reports, and HIV treatment can be independently located and verified.
4. National Institute of Allergy and Infectious Diseases (NIAID), NIH
   • The principal U.S. federal agency funding HIV research and the development of antiretroviral therapy, and an authoritative source on the established mechanisms and treatment of HIV infection.
5. World Health Organization (WHO)
   • Provides global guidance on HIV treatment and on chemical safety, including cyanide hazards, and offers an international regulatory and public-health perspective.
6. U.S. Centers for Disease Control and Prevention (CDC) and Agency for Toxic Substances and Disease Registry (ATSDR)
   • U.S. public-health and toxicological authorities. ATSDR publishes toxicological profiles on cyanide that describe its mechanism, exposure routes, and clinical management.
7. America’s Poison Centers / American Association of Poison Control Centers
   • The poison-control network that has documented and responded to cases of cyanide poisoning from amygdalin, laetrile, and apricot kernels, including paediatric exposures, and provides guidance on the danger of these products.
8. Memorial Sloan Kettering Cancer Center — Integrative Medicine / About Herbs Database
   • A clinical resource that reviews amygdalin and laetrile from evidence-based and toxicological standpoints, summarizing the absence of demonstrated efficacy and the documented risks.
9. National Center for Complementary and Integrative Health (NCCIH), NIH
   • The NIH center that evaluates complementary and alternative approaches, including so-called «vitamin B17,» from the standpoint of scientific evidence and safety.